Proton Therapy vs Photon Radiation for Glioblastoma

Many newly diagnosed glioblastoma patients and their families must choose between proton therapy and standard photon radiation - also called IMRT, or intensity-modulated radiation therapy. Both are delivered five days a week for roughly six weeks with temozolomide chemotherapy. Both target the same tumor area. But they use different physics, and recent randomized trials show that difference matters.

This article explains what separates the two approaches, what the current evidence shows, who may benefit most from proton therapy, and what to ask your radiation oncologist before a plan is finalized.

What is the core difference between proton therapy and photon radiation for GBM?

Photon radiation passes through the body, depositing dose both before and after the tumor. Proton beams slow and stop at a defined depth inside tissue, releasing most of their energy at a point called the Bragg peak and delivering very little dose beyond it. In brain tumors, surrounding healthy brain tissue absorbs less scattered radiation with proton therapy than with IMRT - and that difference matters.

How each approach works

IMRT - photon radiation

IMRT shapes X-ray beams from multiple angles to converge on the tumor. Modern IMRT is precise, but photons still deposit a low dose to tissues both before and after the target. In the brain, those tissues include memory structures such as the hippocampus, the optic pathways, and circulating immune cells in the bloodstream and lymphoid tissue along the dural venous sinuses.

IMRT is the standard of care for glioblastoma. It is available at most major oncology centers and is integrated into the Stupp protocol - the sequence of surgery, chemoradiation, and maintenance chemotherapy that guides GBM treatment. For a walkthrough of how each phase of treatment fits together, see our guide to the Stupp protocol for glioblastoma, phase by phase.

Proton beam therapy

Proton therapy uses charged particles accelerated in a large machine called a cyclotron or synchrotron. The Bragg peak means the beam deposits its maximum energy at a controllable depth and stops. Very little radiation continues beyond that point. Radiation oncologists can use this property to escalate dose to the tumor while reducing exposure to nearby structures.

Proton centers require specialized, large-scale infrastructure. The machines are much larger and more expensive than IMRT systems. This limits availability - most countries have only a small number of proton centers, and some have none.

How does proton therapy compare to standard IMRT for glioblastoma?

The key finding from Phase II data: dose-escalated proton therapy showed a meaningful survival signal while dose-escalated IMRT did not - and the proton group had lower rates of severe lymphopenia. These results are from a Phase II trial, not a confirmed Phase III standard. The definitive trial to confirm or refute this signal is now being designed. Source: NRG Oncology, 2025.

What the clinical evidence actually shows

Until recently, researchers had not rigorously tested proton therapy against IMRT in glioblastoma specifically. Most data came from retrospective analyses. A large review of the National Cancer Data Base comparing proton versus photon treatment in primary gliomas found longer survival in the proton group, but the authors noted that such database studies cannot fully account for patient-selection differences. Proton centers tend to attract younger, healthier patients. That analysis was hypothesis-generating, not definitive. You can review it at PubMed Central.

The most important current evidence comes from the NRG-BN001 randomized Phase II trial - the first NCI-funded randomized proton trial to complete enrollment in glioblastoma. The trial compared standard IMRT plus temozolomide against dose-escalated IMRT and dose-escalated proton therapy. Results presented at the 2025 ASTRO Annual Meeting showed that dose-escalated proton therapy was associated with a hazard ratio for death of 0.81 versus standard treatment. This translates to an absolute survival benefit of 6.8% at two years and 4.6% at three years. Dose-escalated photon IMRT did not show a significant survival benefit in this analysis. The trial is registered at ClinicalTrials.gov (NCT02179086).

A striking finding was the lymphopenia difference. Severe lymphopenia - a drop in circulating lymphocytes, the immune cells that help the body recognize and attack tumor tissue - occurred in 17.1% of the proton group versus 23.4% in the photon group. Research published in Neuro-Oncology found that significant lymphopenia occurs in roughly 30-40% of GBM patients receiving radiation plus temozolomide, and it is independently associated with worse overall survival. The proposed mechanism: radiation to the brain and circulating blood depletes the lymphocytes that would otherwise support an anti-tumor immune response. Proton therapy exposes less surrounding brain and blood to radiation, which may preserve immune function. Whether this immune-sparing effect directly explains the survival signal is still being studied. You can read that analysis at PubMed Central.

Because the NRG-BN001 Phase II analysis met its pre-defined signal threshold, NRG Oncology is now designing a Phase III confirmatory trial. That trial will provide the definitive head-to-head comparison. Until then, proton therapy for newly diagnosed GBM is an evidence-informed option - not yet an established standard alongside IMRT.

In Europe, the multicenter GRIPS trial is separately comparing proton therapy versus IMRT for glioblastoma with a primary focus on toxicity during and shortly after treatment. It is a randomized Phase III study being conducted at centers in Heidelberg, Marburg, and Stuttgart. Secondary endpoints include overall survival, progression-free survival, quality of life, and neurocognition. The study protocol is available at PubMed Central. Results from both the US and European trials will together build the evidence base the field currently lacks.

Re-irradiation is a separate scenario. Patients with recurrent GBM who already completed standard radiation may be candidates for a second course of radiation to the same region. Proton therapy matters more here, since cumulative brain dose limits what can safely be given. A multi-institutional registry analysis found proton re-irradiation for recurrent GBM to be feasible with manageable toxicity - details at PubMed Central.

Who may benefit most from proton therapy for glioblastoma?

Proton therapy is not the better choice for every patient. Radiation oncologists weigh several factors when considering whether to pursue it over standard IMRT.

• Tumor location near critical structures. If the tumor is close to the optic chiasm, brainstem, hippocampus, or language cortex, the proton beam's sharp dose boundary may be most relevant. The benefit depends on where your tumor sits on your imaging.
• MGMT methylation status. Patients whose tumor carries MGMT promoter methylation are expected to respond better to temozolomide and may live longer on average. A longer expected survival means late radiation effects - including cognitive changes from low-dose scatter - matter more over time. Proton therapy's reduced scatter may offer a quality-of-life advantage in this group. For more on how radiation scheduling decisions interact with molecular profiling, see our comparison of hypofractionated versus standard radiation for glioblastoma.
• Younger patients with good performance status. Patients likely to survive two or more years stand to gain more from reduced late toxicity. For older patients or those with significant other health conditions, the advantage of reduced scatter may be less central to their overall treatment goal.
• Recurrent GBM candidates for re-irradiation. When a patient who completed standard radiation develops recurrence, proton therapy is increasingly discussed as a way to safely deliver a second course of radiation to a previously treated brain region.
• Access to a center with specific GBM experience. Proton therapy is only available at specialized centers. Experience with glioblastoma specifically - not just other brain or head-and-neck tumors - matters. Ask directly how many GBM patients the proton program treats annually.

Making this choice is rarely simple, and the right answer depends on your tumor's MRI anatomy, molecular profile, and what is realistically accessible to you. Radiation planning begins quickly after surgery, so raising the question early matters. If you want your pathology and imaging reviewed by specialists before committing to a radiation approach, you can explore precision-oncology options through Art of Healing Cancer - they offer remote case reviews for patients and families facing these decisions.

Access, cost, and practical considerations

Proton centers are concentrated in a small number of countries. The United States has the largest number, primarily at academic medical centers. Established programs exist across Western Europe, Japan, South Korea, and at select centers in India. Cost is a significant barrier in most settings: proton therapy is substantially more expensive than IMRT, and many insurers currently classify proton therapy for GBM as investigational pending Phase III data, which affects coverage decisions. Patients traveling internationally should verify that the proton center has documented, specific experience with glioblastoma and that their home oncologist will coordinate follow-up care. For a detailed breakdown of what treatment costs look like across different healthcare systems, see our guide to GBM treatment costs in the USA, UK, and India.

Questions to ask your radiation oncologist before deciding

• Is there a proton therapy center within feasible travel distance that has specific experience treating GBM?
• Based on my tumor's location on MRI, would proton therapy meaningfully reduce dose to critical nearby structures - or would the dosimetric difference be small in my specific case?
• Am I eligible to enroll in a Phase III proton trial now being developed through NRG Oncology?
• What is my MGMT methylation status, and how should it affect my thinking about late radiation toxicity?
• If I choose standard IMRT now, does that preserve proton re-irradiation as an option if the tumor recurs later?
• What are the logistical requirements - how many sessions, and can any coordination with my local team be arranged for follow-up?

When to talk to your doctor

Radiation planning for GBM typically begins within three to six weeks of surgery. If you want proton therapy considered, raise it early with your neuro-oncologist and ask for a radiation oncology consultation at a proton-capable center before your plan is finalized. Waiting until after standard radiation has started limits what changes are possible. If you are already mid-treatment and have questions about your current radiation approach, discuss those with your oncologist before making any decisions independently.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.